Clinical Trial Update: Vinorelbine Plus (+) Trastuzumab vs Docetaxel Plus (+) Trastuzumab as 1 Line Treatment for HER2 Positive (+) Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update comparing vinorelbine plus trastuzumab versus docetaxel plus trastuzumab as first-line treatment for HER2-positive metastatic br…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Trastuzumab (trastuzumab)
• Vinorelbine (Vinorelbine)

Snippet

Sponsor: Danish Breast Cancer Cooperative Group | Conditions: Breast Cancer | Phase 3 | Status: UNKNOWN